RFG Fact Sheet: Invesco S&P MidCap 400 Pure Growth ETF
Share
$53.84
close, Nov 18, 2026
Over the year to Nov 18, 2026, RFG returned +6.9% in total and charged 0.35% a year.
- 1-year total return
- +6.9%
- to Nov 18, 2026
- Expense ratio
- 0.35%
- a year
- Net assets
- $297m
- on Nov 17, 2026
- Net flow, last 5 trading days
- $0
- daily basis to Nov 17, 2026
Growth of $10,000, 1 year
RFG $10,686 +6.9% · Total return, distributions reinvested, Nov 18, 2025 to Nov 18, 2026.
Returns
WindowTotal return
1 month−6.6%
3 months−14.0%
Year to date+2.7%
1 year+6.9%
3 years+39.5%
5 years+14.1%
Total return, distributions reinvested, each window to Nov 18, 2026.
Ten largest positions
HoldingWeight
Halozyme Therapeutics Inc2.79%
Medpace Holdings Inc2.34%
TechnipFMC PLC2.20%
Five Below Inc2.02%
Exelixis Inc2.01%
Valaris Ltd1.90%
ATI Inc1.84%
Woodward Inc1.81%
InterDigital Inc1.78%
United Therapeutics Corp1.71%
RFG top ten by weight, 20.4% of the fund, of its 101 equity positions, from the holdings published by its issuer for Nov 17, 2026.
Facts
Equity fund · Tracks the S&P MidCap 400 Pure Growth Index · First traded Mar 7, 2006 · Benchmark Its own holdings, as of Nov 17, 2026